S&P 500   5,111.16 (+0.29%)
DOW   39,008.40 (+0.03%)
QQQ   442.19 (+0.73%)
AAPL   179.09 (-0.92%)
MSFT   412.77 (-0.21%)
META   499.88 (+1.99%)
GOOGL   137.87 (-0.43%)
AMZN   177.38 (+0.35%)
TSLA   200.43 (-0.72%)
NVDA   808.13 (+2.15%)
NIO   5.76 (+0.17%)
AMD   201.38 (+4.60%)
BABA   74.56 (+0.72%)
T   16.96 (+0.18%)
F   12.56 (+0.96%)
MU   94.86 (+4.69%)
CGC   3.17 (-3.65%)
GE   158.69 (+1.15%)
DIS   111.92 (+0.30%)
AMC   4.35 (+0.69%)
PFE   26.59 (+0.11%)
PYPL   61.43 (+1.81%)
XOM   105.56 (+1.00%)
S&P 500   5,111.16 (+0.29%)
DOW   39,008.40 (+0.03%)
QQQ   442.19 (+0.73%)
AAPL   179.09 (-0.92%)
MSFT   412.77 (-0.21%)
META   499.88 (+1.99%)
GOOGL   137.87 (-0.43%)
AMZN   177.38 (+0.35%)
TSLA   200.43 (-0.72%)
NVDA   808.13 (+2.15%)
NIO   5.76 (+0.17%)
AMD   201.38 (+4.60%)
BABA   74.56 (+0.72%)
T   16.96 (+0.18%)
F   12.56 (+0.96%)
MU   94.86 (+4.69%)
CGC   3.17 (-3.65%)
GE   158.69 (+1.15%)
DIS   111.92 (+0.30%)
AMC   4.35 (+0.69%)
PFE   26.59 (+0.11%)
PYPL   61.43 (+1.81%)
XOM   105.56 (+1.00%)
S&P 500   5,111.16 (+0.29%)
DOW   39,008.40 (+0.03%)
QQQ   442.19 (+0.73%)
AAPL   179.09 (-0.92%)
MSFT   412.77 (-0.21%)
META   499.88 (+1.99%)
GOOGL   137.87 (-0.43%)
AMZN   177.38 (+0.35%)
TSLA   200.43 (-0.72%)
NVDA   808.13 (+2.15%)
NIO   5.76 (+0.17%)
AMD   201.38 (+4.60%)
BABA   74.56 (+0.72%)
T   16.96 (+0.18%)
F   12.56 (+0.96%)
MU   94.86 (+4.69%)
CGC   3.17 (-3.65%)
GE   158.69 (+1.15%)
DIS   111.92 (+0.30%)
AMC   4.35 (+0.69%)
PFE   26.59 (+0.11%)
PYPL   61.43 (+1.81%)
XOM   105.56 (+1.00%)
S&P 500   5,111.16 (+0.29%)
DOW   39,008.40 (+0.03%)
QQQ   442.19 (+0.73%)
AAPL   179.09 (-0.92%)
MSFT   412.77 (-0.21%)
META   499.88 (+1.99%)
GOOGL   137.87 (-0.43%)
AMZN   177.38 (+0.35%)
TSLA   200.43 (-0.72%)
NVDA   808.13 (+2.15%)
NIO   5.76 (+0.17%)
AMD   201.38 (+4.60%)
BABA   74.56 (+0.72%)
T   16.96 (+0.18%)
F   12.56 (+0.96%)
MU   94.86 (+4.69%)
CGC   3.17 (-3.65%)
GE   158.69 (+1.15%)
DIS   111.92 (+0.30%)
AMC   4.35 (+0.69%)
PFE   26.59 (+0.11%)
PYPL   61.43 (+1.81%)
XOM   105.56 (+1.00%)

Sangamo Therapeutics (SGMO) Competitors

$1.10
-0.06 (-4.74%)
(As of 10:15 AM ET)

SGMO vs. AGEN, CLLS, ATRA, CRIS, IPHA, CGEN, OMGA, SLDB, GRTS, and JSPR

Should you be buying Sangamo Therapeutics stock or one of its competitors? The main competitors of Sangamo Therapeutics include Agenus (AGEN), Cellectis (CLLS), Atara Biotherapeutics (ATRA), Curis (CRIS), Innate Pharma (IPHA), Compugen (CGEN), Omega Therapeutics (OMGA), Solid Biosciences (SLDB), Gritstone bio (GRTS), and Jasper Therapeutics (JSPR). These companies are all part of the "medical" sector.

Sangamo Therapeutics vs.

Agenus (NASDAQ:AGEN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation.

Sangamo Therapeutics has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agenus$100.90M2.65-$220.07M-$0.82-0.82
Sangamo Therapeutics$111.30M1.76-$192.28M-$1.45-0.76

55.4% of Agenus shares are owned by institutional investors. Comparatively, 59.8% of Sangamo Therapeutics shares are owned by institutional investors. 4.8% of Agenus shares are owned by company insiders. Comparatively, 3.0% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Agenus had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 6 mentions for Agenus and 3 mentions for Sangamo Therapeutics. Agenus' average media sentiment score of 0.94 beat Sangamo Therapeutics' score of 0.63 indicating that Sangamo Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agenus
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sangamo Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Agenus received 25 more outperform votes than Sangamo Therapeutics when rated by MarketBeat users. Likewise, 70.38% of users gave Agenus an outperform vote while only 62.73% of users gave Sangamo Therapeutics an outperform vote.

CompanyUnderperformOutperform
AgenusOutperform Votes
461
70.38%
Underperform Votes
194
29.62%
Sangamo TherapeuticsOutperform Votes
436
62.73%
Underperform Votes
259
37.27%

Agenus presently has a consensus price target of $8.10, suggesting a potential upside of 1,086.81%. Sangamo Therapeutics has a consensus price target of $4.68, suggesting a potential upside of 303.02%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Agenus is more favorable than Sangamo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Sangamo Therapeutics
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29

Sangamo Therapeutics has a net margin of -123.88% compared to Sangamo Therapeutics' net margin of -280.44%. Sangamo Therapeutics' return on equity of 0.00% beat Agenus' return on equity.

Company Net Margins Return on Equity Return on Assets
Agenus-280.44% N/A -73.24%
Sangamo Therapeutics -123.88%-61.40%-39.63%

Agenus has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Sangamo Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Summary

Agenus beats Sangamo Therapeutics on 11 of the 18 factors compared between the two stocks.


Get Sangamo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SGMO vs. The Competition

MetricSangamo TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$195.97M$2.72B$4.95B$7.54B
Dividend YieldN/A2.38%2.87%3.87%
P/E Ratio-0.7617.21188.3714.15
Price / Sales1.76260.303,003.0474.91
Price / CashN/A29.9396.0754.95
Price / Book0.614.494.534.68
Net Income-$192.28M-$6.09M$114.14M$211.39M
7 Day Performance-2.21%4.89%4.83%2.59%
1 Month Performance121.00%14.21%9.35%5.39%
1 Year Performance-62.54%12.24%12.70%8.68%

Sangamo Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGEN
Agenus
4.4026 of 5 stars
$0.67
+1.5%
$8.10
+1,111.8%
-67.5%$254.99M$98.02M-0.82533High Trading Volume
CLLS
Cellectis
2.4075 of 5 stars
$2.73
-5.5%
$9.75
+257.1%
+16.7%$151.73M$25.73M-1.63231Positive News
Gap Down
ATRA
Atara Biotherapeutics
4.1299 of 5 stars
$0.84
+9.1%
$28.00
+3,231.7%
-80.8%$85.65M$63.57M-0.30334Upcoming Earnings
Short Interest ↑
News Coverage
CRIS
Curis
1.7695 of 5 stars
$10.14
-3.3%
$37.33
+268.2%
-18.1%$59.77M$10.02M-1.1349Short Interest ↑
IPHA
Innate Pharma
1.4343 of 5 stars
$2.60
+2.4%
$9.83
+278.2%
-11.2%$210.24M$60.78M0.00191Short Interest ↑
CGEN
Compugen
1.7888 of 5 stars
$2.40
flat
$5.33
+122.2%
+226.5%$207.89M$7.50M-6.4969Short Interest ↑
OMGA
Omega Therapeutics
3.0784 of 5 stars
$3.89
-9.3%
$11.40
+193.1%
-36.4%$214.50M$2.07M-1.87116Upcoming Earnings
News Coverage
SLDB
Solid Biosciences
1.6466 of 5 stars
$10.10
+0.8%
$9.00
-10.9%
+67.1%$203.82M$8.09M-2.2387Short Interest ↑
Gap Up
GRTS
Gritstone bio
1.668 of 5 stars
$2.12
-1.9%
$7.33
+245.9%
+14.3%$202.12M$19.94M-1.71233Analyst Report
News Coverage
Gap Down
JSPR
Jasper Therapeutics
2.7028 of 5 stars
$19.44
+2.6%
$59.63
+206.7%
+10.1%$216.91MN/A-2.3435Gap Up

Related Companies and Tools

This page (NASDAQ:SGMO) was last updated on 3/1/2024 by MarketBeat.com Staff